Welcome to the Site for the
Prescription Drug Monitoring Program
On May 10, 2011, Governor Martin O’Malley signed into law Senate Bill 883
, legislation to create a Prescription Drug Monitoring Program (PDMP) in Maryland. The goal of the PDMP is to reduce the non-medical use, abuse and diversion of prescription drugs while preserving legitimate patient access to optimal pharmaceutical-assisted care. The PDMP will monitor the prescribing and dispensing of Controlled Dangerous Substances (drugs with abuse potential
), including opioid pain relievers like oxycodone (OxyContin, Percocet, Percodan, Roxicet), hydrocodone (Vicodin, Lortab) and methadone prescribed for pain, psychotherapeutics like alprazolam (Xanax) and diazepam (Valium), and stimulants like Adderall and Ritalin.
The program will make prescription information available only to a limited, statutorily-defined group of individuals and organizations responsible for ensuring the health and welfare of patients and the lawful use of controlled substances. For the first time, comprehensive information on controlled substances prescribed and dispensed will be made available to doctors, pharmacists and other healthcare providers. The PDMP will provide a powerful clinical tool for the prevention, early identification, and treatment of prescription drug abuse and addiction. The program will also assist bona fide investigations by law enforcement, licensing and regulatory agencies to reduce the diversion of controlled substances to the illegal market.
In partnership with government agencies, universities, non-profits, professional societies and other stakeholders, the PDMP will develop and make available training and educational resources on the appropriate clinical use of controlled substances and prescription drug-related abuse and addiction to healthcare practitioners, policymakers, researchers and the general public.
When compared with demographic data on other substance-abuse treatment admissions, prescription-drug abuse appears to be having a disproportionate impact on young people, women, whites, and those living in rural areas. In FY 2011, 42% of benzodiazepine-related and 47% of prescription-opioid-related treatment admissions involved people in their twenties compared to 30% overall. Eighty-eight percent of benzodiazepine-related and 84% of opioid-analgesic-related admissions were white, compared to 55% of total admissions. About a third of total treatment admissions were female compared to 43% of opioid analgesic-related and half of benzodiazepine-related admissions. Maryland’s more rural counties were clearly the leaders in opioid analgesic-related treatment admissions. For the state population over age 14, the FY 2011 rate of opioid-analgesic-related admissions per 100,000 was 158.6; the highest rates by subdivision occurred among residents of Calvert (736.2), Cecil (587.9), Kent (502.1), Caroline (463.8), Wicomico (429.3), St. Mary’s (420.7), Garrett (346.9) and Allegany (345.8) counties. This map displays the distribution of rates, showing the rural concentration of prescription-opioid problems. The counties with the highest percentage increases in opioid-analgesic-related admissions from FY 2007 to FY 2011 were Wicomico (394%), Caroline (392%), Cecil (307.8%), Harford (281.6%), Worcester (279.4%), Frederick (262.9%), Charles (247.1%), and Calvert (218.3%). The statewide increase was 135.2%, including a 269% increase in out-of-state residents entering Maryland programs for treatment of opioid-analgesic problems.
CRISP PDMP Request for Proposals